Interstitial Lung Disease Induced by Anti-ERBB2 Antibody-Drug Conjugates: A Review | Breast Cancer | JN Learning | AMA Ed Hub [Skip to Content]
[Skip to Content Landing]

Interstitial Lung Disease Induced by Anti-ERBB2 Antibody-Drug ConjugatesA Review

Educational Objective
To learn the diagnosis and management of interstitial lung disease induced by anti-ERBB2 antibody-drug conjugates (ADCs).
1 Credit CME
Abstract

Importance  In the past decade, ERBB2 (formerly HER2)–directed antibody-drug conjugates (ADCs) have substantially changed treatment of both advanced and early-stage ERBB2-positive breast cancer. Novel conjugates are now showing activity in trials of other ERBB2-associated tumors, leading to the recent US Food and Drug Administration approval of trastuzumab deruxtecan for ERBB2-positive gastric cancer, as well as beneficial results in colorectal, lung, and bladder cancer. It is thus possible that anti-ERBB2 ADCs may become a treatment option for multiple types of tumors because many have at least some expression of ERBB2. Despite an improved overall therapeutic index, clinical observations have recently raised a concern regarding potential lung toxicity of anti-ERBB2 ADCs. Deaths related to interstitial lung disease (ILD) have been reported with variable incidence in trials testing anti-ERBB2 conjugates, warranting appropriate training of clinicians for the identification and management of this toxic effect.

Observations  Although no specific guidelines are available for the diagnosis and management of ADC-related ILD, some recommendations can be derived based on general principles adopted for drug-induced and immunotherapy-related ILD. Overall, in symptomatic ILD, the ADC should be discontinued. Reintroduction of the conjugate can be considered only in asymptomatic cases after complete resolution. Corticosteroids represent the cornerstone of ILD treatment, and dosing should be adapted according to the severity of the event. Additional treatments can be considered based on the clinical scenario.

Conclusions and Relevance  This review summarizes the current knowledge on the pathogenesis and epidemiologic characteristics of anti-ERBB2 ADC-related lung toxicity, proposing strategies for its diagnosis and treatment. Earlier diagnosis and more adequate treatment of ADC-induced ILD may improve the therapeutic index of this important class of anticancer agents, allowing for a safe expansion of anti-ERBB2 ADCs across tumor types.

Sign in to take quiz and track your certificates

Buy This Activity

JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 CME Credit™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC

CME Disclosure Statement: Unless noted, all individuals in control of content reported no relevant financial relationships. If applicable, all relevant financial relationships have been mitigated.

Article Information

Accepted for Publication: March 17, 2021.

Published Online: October 14, 2021. doi:10.1001/jamaoncol.2021.3595

Corresponding Author: Giuseppe Curigliano, MD, PhD, Division of Early Drug Development–European Institute of Oncology IRCCS, Via Ripamonti 435, Milan, Italy, 20141 (giuseppe.curigliano@ieo.it).

Author Contributions: Dr Tarantino had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Drs Andrè and Curigliano contributed equally to the work.

Concept and design: Tarantino, Hamilton, Curigliano.

Acquisition, analysis, or interpretation of data: Modi, Tolaney, Cortés, Kim, Toi, Andrè, Curigliano.

Drafting of the manuscript: Tarantino, Hamilton, Curigliano.

Critical revision of the manuscript for important intellectual content: Tarantino, Modi, Tolaney, Cortés, Kim, Toi, Andrè, Curigliano.

Administrative, technical, or material support: Modi, Hamilton, Curigliano.

Supervision: Tarantino, Tolaney, Cortés, Curigliano.

Conflict of Interest Disclosures: Dr Modi reported receiving research funding and speaking/consulting fees from Genentech, Daiichi Sankyo, AstraZeneca, and Seattle Genetics, and consulting fees from MacroGenics during the conduct of the study. Dr Tolaney reported receiving grants from AstraZeneca, Bristol Myers Squibb, Cyclacel Pharmaceuticals, Eisai, Eli Lilly, Exelixis, Genentech/Roche, Immunomedics/Gilead studies, Merck, NanoString, Nektar, Novartis, Odonate, Pfizer, Sanofi, and Seattle Genetics to the institution outside the submitted work; she also reported receiving honoraria for consultant or advisory board service from AstraZeneca, Athenex, Bristol Myers Squibb, Certara, CytomX, Daiichi Sankyo, Eisai, Eli Lilly, Genentech/Roche, Immunomedics/Gilead, Kyowa Kirin Pharmaceuticals, Merck, Mersana Therapeutics, NanoString, Nektar, Novartis, Odonate, OncoPep, Pfizer, Puma Biotechnology, Samsung Bioepis, Sanofi, and Seattle Genetics. Dr Cortés reported receiving honoraria for consulting from Daiichi Sankyo and AstraZeneca during the conduct of the study; honoraria for consulting from Roche, Celgene, Cellestia, Bio-Thera, Merus, Seattle Genetics, Erytech, Athenex, Polyphor, Lilly, Servier, Merck Sharp & Dohme, GSK, Leuko, Bioasis, Clovis Oncology, Boehringer Ingelheim, Novartis, Eisai, Pfizer, Samsung Bioepis, and Kyowa Kyrin outside the submitted work; and holding stock in MedSIR. Dr Hamilton reported research funding to the institution from OncoMed Research, Genentech/Roche, Zymeworks, Rgenix, ArQule, Clovis, Silverback Therapeutics, Millennium Pharmaceuticals, Medivation, Acerta Pharma, Sermonix, Aravive, Torque, Black Diamond, Karyopharm, Infinity Pharmaceuticals, Curis, Syndax, Novartis, Boehringer Ingelheim, Immunomedics, Fujifilm, Taiho, Deciphera, Fochon, Molecular Templates, Onconova, Dana-Farber Cancer Hospital, Hutchinson MediPharma, MedImmune, Seagen, Puma Biotechnology, Compugen, TapImmune, Lilly, Pfizer, H3 Biomedicine, Takeda, Merus, Regeneron, Arvinas, StemCentRx, Verastem, eFFECTOR Therapeutics, CytomX, InventisBio, Lycera, Mersana, Radius Health, AbbVie, NuCana, Leap Therapeutics, Zenith, Harpoon, Orinove, AstraZeneca, Tesaro, MacroGenics, EMD Serono, Daiichi Sankyo, Syros, Sutro, G1 Therapeutics, Merck, PharmaMar, Olema, Polyphor, Immunogen, Plexxicon, and Amgen; advisory fees paid to the institution from Genentech/Roche, Boehringer Ingelheim, Novartis, Dantari, Lilly, Merck, Puma Biotechnology, Silverback Therapeutics, CytomX, Pfizer, Mersana, Black Diamond, H3 Biomedicine, Daiichi Sankyo, and AstraZeneca outside the submitted work. Dr Kim reported receiving research funding to the institution from Novartis and Sanofi Genzyme. Dr Toi reported receiving grants from Chugai; lecture honoraria and grants from Daiichi Sankyo; and lecture and advisory honoraria for drug development during the conduct of the study; grants and lecture honoraria from Takeda, Pfizer, Kyowa Kirin, and Taiho; grants from the JBCRG Association, Eisai, AstraZeneca, and Eli Lilly; honoraria for lecture and as an advisor for drug development from Exact Sciences; honoraria for lecture from Novartis; grants from Astellas; honoraria as an advisor for drug development from Bristol Myers Squibb; grants and lecture honoraria from Shimadzu Yakult and Nippon Kayaku; grants from AFI Technologies; honoraria as an advisor from Athenex Oncology; honoraria as an advisor for drug development from Bertis; honoraria as an advisor for device development from Terumo; grants for device development from Luxonus; grants from Shionogi Research and GL Sciences; honoraria for an advisory role from Kansai Medical Net outside the submitted work; and honoraria for serving on the board of directors for JBCRG Association, Kyoto Breast Cancer Research Network, and Organisation for Oncology and Translational Research. Dr Andre reported receiving grants to the institution from Novartis, Roche, Pfizer, AstraZeneca, Daiichi Sankyo, and Lilly outside the submitted work. Dr Curigliano reported receiving honoraria for lectures and serving on the Daiichi Sankyo advisory board, grants from Merck for investigator-initiated research, and serving on the advisory boards of AstraZeneca, Bristol Myers Squibb, Roche, Lilly, Pfizer, Novartis, Exact Sciences, and Seagen outside the submitted work. No other disclosures were reported.

References
1.
Amiri-Kordestani  L , Blumenthal  GM , Xu  QC ,  et al.  FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer.   Clin Cancer Res. 2014;20(17):4436-4441. doi:10.1158/1078-0432.CCR-14-0012 PubMedGoogle ScholarCrossref
2.
Wedam  S , Fashoyin-Aje  L , Gao  X ,  et al.  FDA approval summary: ado-trastuzumab emtansine for the adjuvant treatment of HER2-positive early breast cancer.   Clin Cancer Res. 2020;26(16):4180-4185. doi:10.1158/1078-0432.CCR-19-3980 PubMedGoogle ScholarCrossref
3.
Modi  S , Saura  C , Yamashita  T ,  et al; DESTINY-Breast01 Investigators.  Trastuzumab deruxtecan in previously treated HER2-positive breast cancer.   N Engl J Med. 2020;382(7):610-621. doi:10.1056/NEJMoa1914510 PubMedGoogle ScholarCrossref
4.
Shitara  K , Bang  Y-J , Iwasa  S ,  et al; DESTINY-Gastric01 Investigators.  Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer.   N Engl J Med. 2020;382(25):2419-2430. doi:10.1056/NEJMoa2004413 PubMedGoogle ScholarCrossref
5.
Enhertu. Prescribing information. January 2021. Accessed January 18, 2021. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761139s011lbl.pdf
6.
Li BT, Smit EF, Goto Y, et al. Trastuzumab deruxtecan in HER2-mutant non–small-cell lung cancer.  N Engl J Med. Published online September 18, 2021. doi:10.1056/NEJMoa2112431
7.
Li  BT , Shen  R , Buonocore  D ,  et al.  Ado-trastuzumab emtansine for patients with HER2-mutant lung cancers: results from a phase II basket trial.   J Clin Oncol. 2018;36(24):2532-2537. doi:10.1200/JCO.2018.77.9777 PubMedGoogle ScholarCrossref
8.
Siena  S , Di Bartolomeo  M , Raghav  KPS ,  et al.  A phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): DESTINY-CRC01  [abstract].  J Clin Oncol. 2020;38(15)(suppl):4000. doi:10.1200/JCO.2020.38.15_suppl.4000Google Scholar
9.
Sheng  X , Yan  X , Wang  L ,  et al.  Open-label, multicenter, phase II study of RC48-ADC, a HER2-targeting antibody-drug conjugate, in patients with locally advanced or metastatic urothelial carcinoma.   Clin Cancer Res. 2021;27(1):43-51. doi:10.1158/1078-0432.CCR-20-2488 PubMedGoogle ScholarCrossref
10.
Tarantino  P , Hamilton  E , Tolaney  SM ,  et al.  HER2-low breast cancer: pathological and clinical landscape.   J Clin Oncol. 2020;38(17):1951-1962. doi:10.1200/JCO.19.02488 PubMedGoogle ScholarCrossref
11.
Banerji  U , van Herpen  CML , Saura  C ,  et al.  Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study.   Lancet Oncol. 2019;20(8):1124-1135. doi:10.1016/S1470-2045(19)30328-6 PubMedGoogle ScholarCrossref
12.
Yamaguchi  K , Bang  Y-J , Iwasa  S ,  et al.  1422MO Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-low, advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: results of the exploratory cohorts in the phase II, multicenter, open-label DESTINY-Gastric01 study  [abstract].  Ann Oncol. 2020;31(suppl 4):S899-S900. doi:10.1016/j.annonc.2020.08.1928Google ScholarCrossref
13.
Powell  C , Camidge  D , Gemma  A ,  et al. Characterization, monitoring and management of interstitial lung disease in patients with metastatic breast cancer: analysis of data available from multiple studies of DS-8201a, a HER2-targeted ADC with a topoisomerase I inhibitor payload. San Antonio Breast Cancer Symposium; December 4-8, 2018; https://sabcs18.posterview.com/nosl/p/P6-17-06
14.
Hackshaw  MD , Danysh  HE , Singh  J ,  et al.  Incidence of pneumonitis/interstitial lung disease induced by HER2-targeting therapy for HER2-positive metastatic breast cancer.   Breast Cancer Res Treat. 2020;183(1):23-39. doi:10.1007/s10549-020-05754-8 PubMedGoogle ScholarCrossref
15.
Powell  CA , Camidge  DR , Modi  S ,  et al:  289P Risk factors for interstitial lung disease in patients treated with trastuzumab deruxtecan from two interventional studies.   Ann Oncol 31(suppl 4):S357-S358, 2020. doi:10.1016/j.annonc.2020.08.391Google ScholarCrossref
16.
Geyer  CE , Untch  M , Prat  A ,  et al.  Trastuzumab deruxtecan (T-DXd; DS-8201) vs trastuzumab emtansine (T-DM1) in high-risk patients with HER2-positive, residual, invasive, early breast cancer after neoadjuvant therapy: a randomized phase 3 trial (DESTINY-Breast05)  [abstract].  Cancer Res. 2021;81(suppl 4):OT-03-OT-01.Google Scholar
17.
Schwaiblmair  M , Behr  W , Haeckel  T , Märkl  B , Foerg  W , Berghaus  T .  Drug induced interstitial lung disease.   Open Respir Med J. 2012;6:63-74. doi:10.2174/1874306401206010063 PubMedGoogle ScholarCrossref
18.
Skeoch  S , Weatherley  N , Swift  AJ ,  et al.  Drug-induced interstitial lung disease: a systematic review.   J Clin Med. 2018;7(10):356. doi:10.3390/jcm7100356 PubMedGoogle ScholarCrossref
19.
Izbicki  G , Segel  MJ , Christensen  TG , Conner  MW , Breuer  R .  Time course of bleomycin-induced lung fibrosis.   Int J Exp Pathol. 2002;83(3):111-119. doi:10.1046/j.1365-2613.2002.00220.x PubMedGoogle ScholarCrossref
20.
Tamiya  A , Naito  T , Miura  S ,  et al.  Interstitial lung disease associated with docetaxel in patients with advanced non–small cell lung cancer.   Anticancer Res. 2012;32(3):1103-1106.PubMedGoogle Scholar
21.
Inaba  K , Arimoto  T , Hoya  M ,  et al.  Interstitial pneumonitis induced by pegylated liposomal doxorubicin in a patient with recurrent ovarian cancer.   Med Oncol. 2012;29(2):1255-1257. doi:10.1007/s12032-011-9893-0 PubMedGoogle ScholarCrossref
22.
Jacobs  C , Slade  M , Lavery  B .  Doxorubicin and BOOP: a possible near fatal association.   Clin Oncol (R Coll Radiol). 2002;14(3):262. doi:10.1053/clon.2002.0071 PubMedGoogle ScholarCrossref
23.
Mazzotta  M , Giusti  R , Iacono  D , Lauro  S , Marchetti  P .  Pulmonary fibrosis after pegylated liposomal doxorubicin in elderly patient with cutaneous angiosarcoma.   Case Rep Oncol Med. 2016;2016:8034832. doi:10.1155/2016/8034832 PubMedGoogle Scholar
24.
Yoshii  N , Suzuki  T , Nagashima  M , Kon  A , Kakihata  K , Gemma  A .  Clarification of clinical features of interstitial lung disease induced by irinotecan based on postmarketing surveillance data and spontaneous reports.   Anticancer Drugs. 2011;22(6):563-568. doi:10.1097/CAD.0b013e3283473f28 PubMedGoogle ScholarCrossref
25.
Willemsen  AECAB , Grutters  JC , Gerritsen  WR , van Erp  NP , van Herpen  CM , Tol  J .  mTOR inhibitor–induced interstitial lung disease in cancer patients: comprehensive review and a practical management algorithm.   Int J Cancer. 2016;138(10):2312-2321. doi:10.1002/ijc.29887 PubMedGoogle ScholarCrossref
26.
Shah  RR .  Tyrosine kinase inhibitor-induced interstitial lung disease: clinical features, diagnostic challenges, and therapeutic dilemmas.   Drug Saf. 2016;39(11):1073-1091. doi:10.1007/s40264-016-0450-9 PubMedGoogle ScholarCrossref
27.
Delaunay  M , Cadranel  J , Lusque  A ,  et al.  Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients.   Eur Respir J. 2017;50(2):1700050. doi:10.1183/13993003.00050-2017 PubMedGoogle Scholar
28.
Raschi  E , Fusaroli  M , Ardizzoni  A ,  et al.  Cyclin-dependent kinase 4/6 inhibitors and interstitial lung disease in the FDA adverse event reporting system: a pharmacovigilance assessment.   Breast Cancer Res Treat. 2021;186(1):219-227. doi:10.1007/s10549-020-06001-w PubMedGoogle ScholarCrossref
29.
Wolska-Washer  A , Robak  T .  Safety and tolerability of antibody-drug conjugates in cancer.   Drug Saf. 2019;42(2):295-314. doi:10.1007/s40264-018-0775-7 PubMedGoogle ScholarCrossref
30.
Crystal  RG , Gadek  JE , Ferrans  VJ , Fulmer  JD , Line  BR , Hunninghake  GW .  Interstitial lung disease: current concepts of pathogenesis, staging and therapy.   Am J Med. 1981;70(3):542-568. doi:10.1016/0002-9343(81)90577-5 PubMedGoogle ScholarCrossref
31.
Drago  JZ , Modi  S , Chandarlapaty  S .  Unlocking the potential of antibody-drug conjugates for cancer therapy.   Nat Rev Clin Oncol. 2021;18(6):327-344. doi:10.1038/s41571-021-00470-8 PubMedGoogle ScholarCrossref
32.
Servier Medical Art templates. Creative Commons Attribution 3.0 Unported License. Accessed March 1, 2021. https://smart.servier.com
33.
Kumagai  K , Aida  T , Tsuchiya  Y , Kishino  Y , Kai  K , Mori  K .  Interstitial pneumonitis related to trastuzumab deruxtecan, a human epidermal growth factor receptor 2-targeting Ab-drug conjugate, in monkeys.   Cancer Sci. 2020;111(12):4636-4645. doi:10.1111/cas.14686 PubMedGoogle ScholarCrossref
34.
Press  MF , Cordon-Cardo  C , Slamon  DJ .  Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues.   Oncogene. 1990;5(7):953-962.PubMedGoogle Scholar
35.
Spira  A , Lisberg  A , Sands  J ,  et al.  Datopotamab deruxtecan (Dato-DXd; DS-1062), a TROP2 ADC, in patients with advanced NSCLC: updated results of TROPION-PanTumor01phase 1 study.   J Thorac Oncol. 2021;16(suppl 3):S106-S107. doi:10.1016/j.jtho.2021.01.280Google ScholarCrossref
36.
von Minckwitz  G , Huang  CS , Mano  MS ,  et al.  Trastuzumab emtansine for residual invasive HER2-positive breast cancer.   N Engl J Med.  2019;380(7):617-628. 2018;1-12. doi:10.1056/NEJMoa1814017 PubMedGoogle ScholarCrossref
37.
Emens  LA , Esteva  FJ , Beresford  M ,  et al.  Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial.   Lancet Oncol. 2020;21(10):1283-1295. doi:10.1016/S1470-2045(20)30465-4 PubMedGoogle ScholarCrossref
38.
Modi  S , Saura  C , Yamashita  T ,  et al.  Updated results from DESTINY-Breast01, a phase 2 trial of trastuzumab deruxtecan (T-DXd) in HER2 positive metastatic breast cancer  [abstract].  Cancer Res. 2021;81(suppl 4):PD3-PD06.Google Scholar
39.
Cortes J, Kim S-B, Chung W-P, et al. LBA1—trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (Pts) with HER2+ metastatic breast cancer (mBC): results of the randomized phase III DESTINY-Breast03 study.  Ann Oncol. 2021;32(suppl 5):S1283-S1346. doi:10.1016/annonc/annonc741
40.
Hamilton  EP , Shapiro  C , Petrylak  D ,  et al.  Trastuzumab deruxtecan (T-DXd; DS-8201) with nivolumab in patients with HER2-expressing, advanced breast cancer: a 2-part, phase 1b, multicenter, open-label study.   Cancer Res. 2021;81(suppl 4):PD3-PD07.Google Scholar
41.
Saura C, O’Shaughnessy J, Aftimos P, et al. LBA15—primary outcome of the phase III SYD985.002/TULIP trial comparing [vic-]trastuzumab duocarmazine to physician’s choice treatment in patients with pre-treated HER2-positive locally advanced or metastatic breast cancer.  Ann Oncol. 2021;32(suppl 5):S1283-S1346. doi:10.1016/annonc/annonc741
42.
Powell  CA , Camidge  DR , Modi  S ,  et al.  Risk factors for interstitial lung disease in patients treated with trastuzumab deruxtecan from two interventional studies  [abstract].  Ann Oncol. 2020;31(suppl 4):289P. doi:10.1016/j.annonc.2020.08.391Google ScholarCrossref
43.
Kubo  K , Azuma  A , Kanazawa  M ,  et al; Japanese Respiratory Society Committee for Formulation of Consensus Statement for the Diagnosis and Treatment of Dug-induced Lung Injuries.  Consensus statement for the diagnosis and treatment of drug-induced lung injuries.   Respir Investig. 2013;51(4):260-277. doi:10.1016/j.resinv.2013.09.001 PubMedGoogle ScholarCrossref
44.
Ng  M-Y , Lee  EYP , Yang  J ,  et al.  Imaging profile of the COVID-19 infection: radiologic findings and literature review.   Radiol Cardiothorac Imaging. 2020;2(1):e200034. doi:10.1148/ryct.2020200034 PubMedGoogle Scholar
45.
Struyf  T , Deeks  JJ , Dinnes  J ,  et al; Cochrane COVID-19 Diagnostic Test Accuracy Group.  Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19 disease.   Cochrane Database Syst Rev. 2020;7:CD013665.PubMedGoogle Scholar
46.
National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE). Accessed September 14, 2021. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm
47.
Jee  AS , Adelstein  S , Bleasel  J ,  et al.  Role of autoantibodies in the diagnosis of connective-tissue disease ILD (CTD-ILD) and interstitial pneumonia with autoimmune features (IPAF).   J Clin Med. 2017;6(5):51. doi:10.3390/jcm6050051 PubMedGoogle ScholarCrossref
48.
Yamakawa  H , Hagiwara  E , Kitamura  H ,  et al.  Serum KL-6 and surfactant protein-D as monitoring and predictive markers of interstitial lung disease in patients with systemic sclerosis and mixed connective tissue disease.   J Thorac Dis. 2017;9(2):362-371. doi:10.21037/jtd.2017.02.48 PubMedGoogle ScholarCrossref
49.
Lee  JS , Lee  EY , Ha  Y-J , Kang  EH , Lee  YJ , Song  YW .  Serum KL-6 levels reflect the severity of interstitial lung disease associated with connective tissue disease.   Arthritis Res Ther. 2019;21(1):58. doi:10.1186/s13075-019-1835-9 PubMedGoogle ScholarCrossref
50.
Elhai  M , Avouac  J , Allanore  Y .  Circulating lung biomarkers in idiopathic lung fibrosis and interstitial lung diseases associated with connective tissue diseases: where do we stand?   Semin Arthritis Rheum. 2020;50(3):480-491. doi:10.1016/j.semarthrit.2020.01.006 PubMedGoogle ScholarCrossref
51.
Chetta  A , Marangio  E , Olivieri  D .  Pulmonary function testing in interstitial lung diseases.   Respiration. 2004;71(3):209-213. doi:10.1159/000077416 PubMedGoogle ScholarCrossref
52.
Costabel  U , Uzaslan  E , Guzman  J .  Bronchoalveolar lavage in drug-induced lung disease.   Clin Chest Med. 2004;25(1):25-35. doi:10.1016/S0272-5231(03)00143-6 PubMedGoogle ScholarCrossref
53.
Padley  SPG , Adler  B , Hansell  DM , Müller  NL .  High-resolution computed tomography of drug-induced lung disease.   Clin Radiol. 1992;46(4):232-236. doi:10.1016/S0009-9260(05)80161-8 PubMedGoogle ScholarCrossref
54.
Müller  NL , White  DA , Jiang  H , Gemma  A .  Diagnosis and management of drug-associated interstitial lung disease.   Br J Cancer. 2004;91(suppl 2):S24-S30. doi:10.1038/sj.bjc.6602064 PubMedGoogle ScholarCrossref
55.
Akira  M , Ishikawa  H , Yamamoto  S .  Drug-induced pneumonitis: thin-section CT findings in 60 patients.   Radiology. 2002;224(3):852-860. doi:10.1148/radiol.2243011236 PubMedGoogle ScholarCrossref
56.
Rossi  SE , Erasmus  JJ , McAdams  HP , Sporn  TA , Goodman  PC .  Pulmonary drug toxicity: radiologic and pathologic manifestations.   Radiographics. 2000;20(5):1245-1259. doi:10.1148/radiographics.20.5.g00se081245 PubMedGoogle ScholarCrossref
57.
Haanen  JBAG , Carbonnel  F , Robert  C ,  et al; ESMO Guidelines Committee.  Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up.   Ann Oncol. 2017;28(suppl_4):iv119-iv142. doi:10.1093/annonc/mdx225 PubMedGoogle ScholarCrossref
58.
Brahmer  JR , Lacchetti  C , Schneider  BJ ,  et al; National Comprehensive Cancer Network.  Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline.   J Clin Oncol. 2018;36(17):1714-1768. doi:10.1200/JCO.2017.77.6385 PubMedGoogle ScholarCrossref
59.
Kadcyla. Prescribing information. May 2019. Accessed January 5, 2020. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125427s105lbl.pdf
60.
Enhertu. Prescribing information. December 2019. Accessed January 5, 2020. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761139s000lbl.pdf
61.
ESMO. Primary outcomes of the multi-center multinational randomized phase III SYD985.002/TULIP trial comparing [vic-]trastuzumab duocarmazine to physician’s choice combination chemotherapy in patients with pretreated HER2-positive locally advanced or metastatic breast cancer. ESMO 2021; September 18, 2021; virtual meeting. Accessed September 14, 2021. https://www.esmo.org/meetings/esmo-congress-2021/press-media
62.
Balaji  A , Hsu  M , Lin  CT ,  et al.  Steroid-refractory PD-(L)1 pneumonitis: incidence, clinical features, treatment, and outcomes.   J Immunother Cancer. 2021;9(1):e001731. doi:10.1136/jitc-2020-001731 PubMedGoogle Scholar
63.
Moore  H , Shofer  S , Guisinger  A ,  et al.  Feasibility of a comprehensive monitoring protocol for the prevention and treatment of interstitial lung disease in patients undergoing treatment with fam-trastuzumab deruxtecan—a retrospective review.   Cancer Res. 2021;81(suppl 4):PS13-PS33.Google Scholar
64.
Imaging biomarker in cancer drug induced ILD (ImageILD). ClinicalTrials.gov identifier: NCT03294746. Updated September 29, 2017. Accessed March 1, 2021. https://clinicaltrials.gov/ct2/show/NCT03294746
65.
Exhaled breath analysis to predict risk of symptomatic pneumonitis. ClinicalTrials.gov identifier: NCT04040244. Updated December 19, 2020. Accessed March 1, 2021. https://clinicaltrials.gov/ct2/show/NCT04040244
66.
Mobile devices to detect early pneumonitis in stage III NSCLC patients on durvalumab (ON TRAX). ClinicalTrials.gov identifier: NCT04381494. Updated June 18, 2021. Accessed March 1, 2021. https://clinicaltrials.gov/ct2/show/NCT04381494
67.
Corticosteroid regimen in patients with anti-PD-1/PD-L1 induced pneumonitis (PROS-CONS). ClinicalTrials.gov identifier: NCT04036721. Updated February 27, 2020. Accessed March 1, 2021. https://clinicaltrials.gov/ct2/show/NCT04036721
68.
Prophylactic inhaled steroids to reduce radiation pneumonitis frequency and severity in lung cancer patients. ClinicalTrials.gov identifier: NCT03803787. Updated February 10, 2021. Accessed March 1, 2021. https://clinicaltrials.gov/ct2/show/NCT03803787
69.
Infliximab and intravenous immunoglobulin therapy in treating patients with steroid-refractory pneumonitis. ClinicalTrials.gov identifier: NCT04438382. Updated August 20, 2021. Accessed March 1, 2021. https://clinicaltrials.gov/ct2/show/NCT04438382
70.
Takano  M , Sugiyama  T .  UGT1A1 polymorphisms in cancer: impact on irinotecan treatment.   Pharmgenomics Pers Med. 2017;10:61-68. doi:10.2147/PGPM.S108656 PubMedGoogle Scholar
Want full access to the AMA Ed Hub?
After you sign up for AMA Membership, make sure you sign in or create a Physician account with the AMA in order to access all learning activities on the AMA Ed Hub
Buy this activity
Close
Want full access to the AMA Ed Hub?
After you sign up for AMA Membership, make sure you sign in or create a Physician account with the AMA in order to access all learning activities on the AMA Ed Hub
Buy this activity
Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close

Name Your Search

Save Search
Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Close

Lookup An Activity

or

Close

My Saved Searches

You currently have no searches saved.

Close

My Saved Courses

You currently have no courses saved.

Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close